Pharmacokinetics and Exposure-Response Analysis of Venetoclax + Obinutuzumab in Chronic Lymphocytic Leukemia: Phase 1b Study and Phase 3 CLL14 Trial

INTRODUCTION: This study aims to investigate pharmacokinetics (PK) and exposure-response parameters of the 400 mg once-daily venetoclax dose regimen in combination with obinutuzumab, which was approved for the first-line (1L) treatment of chronic lymphocytic leukemia (CLL) based on data from the pha...

Descripción completa

Detalles Bibliográficos
Autores principales: Samineni, Divya, Gibiansky, Leonid, Wang, Bei, Vadhavkar, Shweta, Rajwanshi, Richa, Tandon, Maneesh, Sinha, Arijit, Al-Sawaf, Othman, Fischer, Kirsten, Hallek, Michael, Salem, Ahmed Hamed, Li, Chunze, Miles, Dale
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309146/
https://www.ncbi.nlm.nih.gov/pubmed/35708885
http://dx.doi.org/10.1007/s12325-022-02170-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309146/
https://www.ncbi.nlm.nih.gov/pubmed/35708885
http://dx.doi.org/10.1007/s12325-022-02170-w

Ejemplares similares